Study guide

14.1 Indications for Transfusion

Specialist in Blood Banking, SBB ASCP

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility Routes & Credential Maintenance 1.3 Study Strategy for SBB

2 Donors & Collection

2.1 Donor Qualification 2.2 Collection Methods & Adverse Reactions 2.3 Special Donations

3 Processing, Storage & Component QC

3.1 Processing, Testing & Labeling 3.2 Storage, Transport & Expiration 3.3 Blood Component Quality Control

4 Red Cell & Modified Components

4.1 Whole Blood & Red Blood Cells 4.2 Leukocyte-Reduced, Washed, Frozen & Rejuvenated RBCs 4.3 Irradiated Components 4.4 Granulocytes

5 Platelets, Plasma & Cellular Products

5.1 Platelets 5.2 Plasma & Cryoprecipitated AHF 5.3 Apheresis Products & Fractionation Products 5.4 Hematopoietic Progenitors

6 Genetics, ABO & Rh

6.1 Blood Group Genetics & Molecular Inheritance 6.2 ABO & Lewis Systems 6.3 Rh System 6.4 MNS, P1PK/Globoside & Ii

7 Other Blood Groups & Role in Transfusion

7.1 Kell, Kidd, Duffy & Lutheran 7.2 Other Systems & High/Low-Prevalence Antigens 7.3 HLA, Platelet-Specific & Granulocyte Antigens 7.4 Immunogenicity & Antigen Prevalence

8 Immunology Foundations

8.1 Immune Response 8.2 Immunoglobulins 8.3 Antigen-Antibody Interactions 8.4 Complement

9 Physiology, Hemostasis & HDFN

9.1 Physiology of Blood 9.2 Hemostasis and Coagulation 9.3 HDFN Pathophysiology & Detection 9.4 HDFN Treatment & Prevention

10 Cytopenias & Transplantation

10.1 Immune & Nonimmune Anemia 10.2 Thrombocytopenia & Neutropenia 10.3 Solid Organ Transplantation Support 10.4 Hematopoietic Progenitor Cell Transplantation

11 Routine Serologic Testing

11.1 Blood Grouping Tests 11.2 Antibody Detection & Crossmatch 11.3 Antibody Identification & Clinical Significance 11.4 Direct Antiglobulin Testing & Reagents

12 Special Serologic Methods

12.1 Enzymes, Enhancement Media & Lectins 12.2 Adsorptions, Elutions & Titrations 12.3 Cell Separations, Neutralization & Thiol Reagents 12.4 Chloroquine Diphosphate & EDTA-Glycine Acid

13 Molecular Platforms & Serologic QA

13.1 Molecular Blood Group Techniques 13.2 ELISA, Immunofluorescence, Solid Phase & Column Agglutination 13.3 Serologic Quality Assurance

14 Indications, Component Therapy & PBM

14.1 Indications for Transfusion 14.2 Component Therapy 14.3 Blood Administration & Patient Blood Management

15 Adverse Effects of Transfusion

15.1 Immunologic Transfusion Reactions 15.2 Nonimmunologic Reactions 15.3 Transfusion-Transmitted Diseases

16 Apheresis & Extracorporeal Circulation

16.1 Therapeutic Apheresis 16.2 Extracorporeal Circulation

17 Quality, Safety, Math & Instrumentation

17.1 Quality Assessment & Troubleshooting 17.2 Laboratory Safety 17.3 Laboratory Mathematics 17.4 Instrumentation

18 Laboratory Administration (SBB Only)

18.1 Financial Management 18.2 Operations & Information Technology 18.3 Personnel, Education & Training 18.4 Quality Management, Risk & Tissue Management

14.1 Indications for Transfusion

Key Takeaways Explain This Topic AI

Restrictive RBC transfusion strategies (trigger near Hb 7 g/dL for most stable adults) are noninferior to liberal strategies per TRICC, TRISS, and FOCUS; a fixed number should never override active bleeding or symptomatic instability.

Prophylactic platelet transfusion is generally reserved for counts below 10 x10^9/L in stable hypoproliferative thrombocytopenia, with higher thresholds (20-30, 50, or 100 x10^9/L) for procedures, active bleeding, or CNS/ocular risk.

Plasma corrects multiple coagulation factor deficiencies with bleeding or an invasive procedure; it is never appropriate as an isolated volume expander or to correct an elevated INR with no bleeding risk.

Sickle cell disease with acute chest syndrome, stroke, or preoperative HbS reduction is managed with red cell exchange (erythrocytapheresis) targeting HbS below roughly 30%, not simple transfusion alone.

Massive transfusion protocols activate on physiologic instability and predicted need, not a single lab value, and use ratio-based (near 1:1:1 RBC:plasma:platelet) component support until viscoelastic testing can guide targeted replacement.

Last updated: July 2026

Why indications questions are different at the specialist level

At the generalist level, transfusion indication questions often reduce to "the hemoglobin is low, so transfuse." The SBB exam expects more: it tests whether you know the evidence base behind current thresholds, when a disease-specific exception overrides the general rule, and when the correct answer is to withhold a component rather than release it. Indications for transfusion sit inside ASCP Transfusion Practice content area V.A, and the exam pairs this reasoning with component selection (V.B) and administration/PBM (V.E) in the same case-based question.

Evidence-based RBC transfusion thresholds

Large randomized trials changed practice from a fixed "10/30" rule (hemoglobin 10 g/dL, hematocrit 30%) to individualized restrictive thresholds.

Trial/guideline Population Restrictive trigger tested Result

TRICC (1999) Critically ill ICU patients Hb <=7 g/dL vs <=10 g/dL Restrictive strategy was as safe or safer; abandoned the routine 10/30 rule

FOCUS (2011) Older adults after hip fracture surgery with cardiovascular risk Hb <=8 g/dL vs symptomatic liberal trigger No difference in mortality or functional outcome; restrictive strategy supported

TRISS (2014) Septic shock Hb <=7 g/dL vs <=9 g/dL No mortality benefit from the liberal threshold

AABB clinical practice guideline General hospitalized adults, hemodynamically stable Hb 7-8 g/dL Restrictive strategy is the default; higher threshold reserved for specific risk

The practical exam rule: for a stable, non-bleeding adult , do not transfuse until hemoglobin falls to roughly 7 g/dL , or roughly 8 g/dL for patients with significant cardiovascular disease or active myocardial ischemia, where impaired oxygen delivery carries higher risk. Symptoms of anemia (chest pain, dyspnea, orthostatic hypotension, tachycardia unresponsive to volume) can justify transfusion above the numeric trigger; the number is a floor, not a mandate. Active hemorrhage or hemodynamic instability is managed by clinical response, not a static hemoglobin value at all.

Platelet transfusion criteria

Platelet thresholds scale with bleeding risk, not a single universal number.

Clinical scenario Typical trigger Rationale

Stable hypoproliferative thrombocytopenia, no bleeding, no procedure <10 x10^9/L Spontaneous hemorrhage risk rises sharply below this level

Central line placement, bone marrow biopsy, lumbar puncture <20-30 x10^9/L (institution-specific) Lower bleeding risk than major surgery

  • Major surgery <50 x10^9/L Balances surgical hemostasis against transfusion burden
  • Neurosurgery or ophthalmic surgery <100 x10^9/L Even minor bleeding in a closed space is high-consequence

Active bleeding, DIC, or qualitative platelet dysfunction with hemorrhage Individualized, often <50 x10^9/L (higher for CNS/ocular bleeding) Function matters as much as count

Antiplatelet drug effect or uremic platelet dysfunction can justify transfusion even with a normal count when there is significant bleeding.

Plasma and cryoprecipitate indications

Plasma replaces multiple coagulation factors simultaneously. Appropriate indications include active bleeding or a planned invasive procedure in a patient with a significant coagulopathy from multiple factor deficiency (liver disease, dilutional coagulopathy, massive transfusion), and urgent warfarin reversal when prothrombin complex concentrate is unavailable or contraindicated. Plasma is not appropriate as a volume expander and is not indicated to correct an elevated INR in a patient who is not bleeding and has no imminent procedure — this is a classic exam trap.

Cryoprecipitate concentrates fibrinogen, factor VIII, von Willebrand factor, and factor XIII. Its primary current indication is hypofibrinogenemia with bleeding (fibrinogen typically <100-150 mg/dL), seen in obstetric hemorrhage, DIC, liver disease, and massive transfusion. Factor-specific concentrates have largely replaced cryoprecipitate for isolated factor VIII, von Willebrand disease, or hemophilia management where available.

Massive transfusion: activation and approach

A massive transfusion protocol (MTP) activates based on physiologic instability and predicted need — for example, ongoing hemorrhage with hypotension, or an anticipated requirement of four or more RBC units within an hour, or ten units within 24 hours — not a single fixed hemoglobin trigger. Early MTP management favors ratio-based component support , commonly near 1:1:1 (RBC:plasma:platelet) , which approximates reconstituted whole blood and limits dilutional coagulopathy. As viscoelastic testing (TEG or ROTEM) results become available, therapy shifts to goal-directed, lab-guided replacement . Adjuncts include tranexamic acid (most effective within three hours of traumatic injury), calcium repletion (citrate in large-volume transfusion chelates ionized calcium), avoiding excess crystalloid, and permissive hypotension in trauma before definitive hemorrhage control to avoid "popping the clot" and worsening dilutional coagulopathy.

Specialty populations

Neonates. Small blood volume changes have large physiologic effects, so aliquots are dosed by weight (typically 10-15 mL/kg) from fresh, irradiated, CMV-safe units. Transfusion thresholds vary by postnatal age, weight, and respiratory support rather than a single adult-style number, and exchange transfusion is reserved for severe hemolytic disease of the fetus and newborn or dangerous hyperbilirubinemia.

Sickle cell disease. Simple transfusion treats symptomatic anemia or aplastic crisis, but acute chest syndrome, stroke, and preoperative optimization call for red cell exchange (manual or automated erythrocytapheresis) that reduces HbS to roughly below 30% while avoiding the hyperviscosity that simple top-up transfusion can cause by raising the hematocrit too high. Because this population has elevated alloimmunization risk, extended antigen-matched (commonly Rh and K, sometimes broader) units are preferred, and unnecessary transfusion is avoided given the long-term risk of iron overload.

Oncology/hematology. Prophylactic platelet transfusion at <10 x10^9/L in stable patients is supported by trial evidence (e.g., TOPPS), with higher thresholds during fever, infection, or rapidly falling counts. Irradiated components are required for patients undergoing or recovering from hematopoietic stem cell transplant or receiving purine-analog chemotherapy, to prevent transfusion-associated graft-versus-host disease.